Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vibozilimod - Sun Pharmaceutical Industries

Drug Profile

Vibozilimod - Sun Pharmaceutical Industries

Alternative Names: SCD-044

Latest Information Update: 28 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioprojet; Sun Pharma Advanced Research Company
  • Developer Bioprojet; Sun Pharma Advanced Research Company; Sun Pharmaceutical Industries
  • Class Antipsoriatics; Carboxylic acids; Chlorobenzenes; Oxadiazoles; Piperidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis
  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Europe (PO)
  • 30 Jul 2021 Phase-II clinical trials in Atopic dermatitis in USA (PO) (NCT04684485)
  • 26 Mar 2021 Phase-II clinical trials in Plaque psoriasis in USA (PO) (NCT04566666)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top